

Next Day Biopartners

Australian Public Therapeutics Company Profiles:
1Q'24 Preview



Current as of Jan 16, 2024



www.nextdaybiopartners.com

TABLE OF CONTENTS



COMPANY NAME	PAGE
Actinogen Medical Ltd.....	6
AdAlta.....	7
AFT Pharmaceuticals.....	8
Algorae Pharma.....	9
Alterity Therapeutics Ltd.....	10
Amplia Therapeutics Ltd.....	11
Anatara Lifesciences.....	12
Antisense Therapeutics.....	13
Argenica Therapeutics.....	14
Arovella Therapeutics.....	15
Avita Medical.....	16
Biotron Ltd.....	17
Botanix Pharmaceuticals.....	18
Chimeric Therapeutics.....	19
Clarity Pharmaceuticals.....	20

COMPANY NAME	PAGE
Clinuvel Pharmaceuticals.....	21
CSL Ltd.....	22
Cynata Therapeutics.....	23
Dimerix Ltd.....	24
Firebrick Pharma.....	25
Hexima Ltd.....	26
Immutep Ltd.....	27
Imugene Ltd.....	28
Invion Ltd.....	29
Island Pharmaceuticals.....	30
LTR Pharma.....	31
Mayne Pharma Group.....	32
Mesoblast Ltd.....	33
MGC Pharmaceuticals.....	34
Neuren Pharmaceuticals.....	35

TABLE OF CONTENTS



COMPANY NAME	PAGE
Neuroscientific Biopharma.....	36
Neurotech International.....	37
Noxopharma Ltd.....	38
Nyrada Inc.....	39
Opthea Ltd.....	40
Orthocell Ltd.....	41
Paradigm Biopharma.....	42
Patrys Ltd.....	43
Pharmaust Ltd.....	44
Prescient Therapeutics	45
PYC Therapeutics.....	46
Race Oncology.....	47
Radiopharm Theranostics	48
Recce Pharmaceuticals.....	49
Starpharma Holdings Ltd.....	50

COMPANY NAME	PAGE
Syntara Ltd.....	51
Telix Pharmaceuticals Ltd.....	52
Tissue Repair Ltd.....	53
Vectus Biosystems Ltd.....	54
Zelira Therapeutics.....	55

METHODS



The companies included represent Australian Securities Exchange (ASX)-listed therapeutics companies

- Companies may or may not be dual-listed in the United States or other markets.
- Companies may or may not have headquarters in Australia or New Zealand, now or in the past.
- Companies were excluded based on the following terms:
 - Are not healthcare companies
 - Are healthcare companies, but are generics manufacturers, healthtech-related, or business development corporations whose mission is solely investment-focused
 - Companies previously – but not currently - listed on ASX, whether or not they are based in Australia or New Zealand or are therapeutics companies
- We used an FX rate of ~1.5 Australian Dollar (AUD) to 1 USD. Note that dual-listed ASX stocks may be quoted in AUD or USD; we used AUD throughout for consistency of exchange.

DISCLAIMER



The following is for informational purposes only and should not be relied upon as a basis for investment decisions. Next Day Biopartners, LLC (the “Company”), and any subsidiaries, parents, or clients may maintain positions in the securities discussed in this document. The information contained in this document is current as of the date of publication and is accurate to the best of our knowledge. The Company, and any subsidiaries or parents is under no obligation to update the following on any ongoing basis. This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by the Company about circumstances and events that have not yet taken place. Although the Company believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Actinogen Medical Ltd (ACW.AX)



SUMMARY & FOCUS AREAS

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives. The company is developing Xanamem®, a new therapy for multiple neurological diseases where reducing cortisol inside brain cells could have a positive impact.

COMPANY CHEAT SHEET

Actinogen Medical Limited was founded in NSW, Australia in 1999 and was listed on the Australian Securities Exchange (ASX) in October 2007.

Therapeutic areas	Neurology
Lead asset	Xanamem (11 β -HSD1 inh.)
Platform	No

Financial summary (AUD)	
Market cap	\$60.0M
Price	\$0.02
52wk hi	\$0.10
52wk lo	\$0.02
Avg vol (3m)	1.8M
Shares	2.3B
Cash	\$17.9M

<https://actinogen.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Xanamem						Ph 2b confirmatory in mild/mod Alzheimer's disease
						Ph 2a in major depressive disorder now recruiting
						Fragile X syndrome (no current ongoing trial)
Catalysts	1Q'24	2Q'24	2H'24	Notes		
Xanamem	X	X		MDD / cognitive impairment PoC results		



AdAlta (1AD.AX)



SUMMARY & FOCUS AREAS

AdAlta is an early clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing drug targets that are challenging for other technologies. The company focuses on fibrosis and oncology indications addressed by eight pipeline assets and a discovery platform.



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
AD-214						Ongoing Ph 1 in lung & kidney fibrosis
ADR3						Anti-RANKL i-body in osteoporosis
i-CAR						Undisclosed oncology target, partnered with Carina Biotech

Catalysts	1Q'24	2Q'24	2H'24	Notes
AD-214	X			Completion of Ph 1 extension study
		X	X	Complete outlicensing with pharma or investor syndicate
Platform*	X	X	X	Preclinical updates for i-CAR-T, GZMB-i-PET, and malaria

COMPANY CHEAT SHEET

AdAlta was founded by Dr. Michael Foley (currently Chief Scientist) and was listed on the Australian Securities Exchange (ASX) in August 2016.

Therapeutic areas	Fibrosis; oncology
Lead asset	AD-214 (anti-CXCR4)
Platform	Yes

Financial summary (AUD)	
Market cap	\$13.1M
Price	\$0.02
52wk hi	\$0.05
52wk lo	\$0.02
Avg vol (3m)	459K
Shares	525.8M
Cash	\$17.9M

<https://adalta.com.au/>



AFT Pharmaceuticals (AFT.AX)



SUMMARY & FOCUS AREAS



AFT was founded 23 years ago by Dr Hartley and Marree Atkinson. Since then AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally. The 2015 IPO raised funds to pursue a more aggressive R&D-led growth strategy, and AFT has now returned to profitability. AFT plans to distribute its first dividend in 2024.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Maxigesic						Pain medicine; cold & flu launched in AUS
Pascomer						Topical dermatology medicine
Project KW						Multiple formulations for gastroenterology treatment

Catalysts	1Q'24	2Q'24	2H'24	Notes
Maxigesic	X	X	X	IV (USA) and dry stick filings expected in 2024
Pascomer	X	X	X	Expected dermatology launch (filed 2023)
Project KW	X	X	X	Filing tablet and sachet formulations; launch of combo in 2024

COMPANY CHEAT SHEET

AFT Pharmaceuticals was founded in 2000 and is dual-listed on both the New Zealand and Australian stock exchanges in 2015.

Therapeutic areas	Multiple
Lead asset	Multiple marketed products
Platform	No

Financial summary (AUD)	
Market cap	\$368.3M
Price	\$3.52
52wk hi	\$3.70
52wk lo	\$3.00
Avg vol (3m)	682
Shares	104.9M
Cash	\$6.2M

<https://www.aftpharm.com/>



Algorae Pharma (1AI.AX)



SUMMARY & FOCUS AREAS



Algorae is a clinical-stage pharmaceutical company developing transformative solutions for significant undermet medical needs in the community. In 2023 the company pivoted to increasingly use advanced artificial intelligence computational tools to identify therapeutic drug targets and aid understanding of existing therapeutic assets.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
AI-168						Cannabidiol / undisclosed 505(b)(2) combo for cardio
AI-116						Cannabidiol / undisclosed 505(b)(2) combo for Alzheimer's
AlgoraeOS						Proprietary drug discovery platform

Catalysts	1Q'24	2Q'24	2H'24	Notes
AI-116/ -168	X	X		Preclinical updates due from La Trobe Univ and Monash Univ
NTCELL	X	X	X	*Expecting to engage clinical trial partners sometime in 2024
AlgoraeOS	X	X	X	Ongoing drug discovery with Univ. of New South Wales (NSW)

COMPANY CHEAT SHEET

Algorae Pharma was founded in 1987 as Living Cell Technologies and listed on the Australian Securities Exchange (ASX) in September 2004.

Therapeutic areas	Neurology; cardio
Lead asset	AI-168 (CBD + 505(b)(2))
Platform	Yes

Financial summary (AUD)	
Market cap	\$16.6M
Price	\$0.01
52wk hi	\$0.02
52wk lo	\$0.01
Avg vol (3m)	977K
Shares	1.7B
Cash	\$4.1M

<https://algoraepharma.com/>



Alterity Therapeutics Ltd (ATH.AX)



SUMMARY & FOCUS AREAS

Alterity (formerly Prana Biotechnology) is a Melbourne-based biotechnology company focused on creating an alternate future for people living with neurodegenerative diseases. The company has two ongoing mid-stage trials and a drug discovery engine focused on new therapies for multiple neurodegenerative diseases.



COMPANY CHEAT SHEET

Alterity Therapeutics (nee Prana) was founded in 1997 and listed on the ASX in March 2000, with ADSs listed on the NASDAQ.

Therapeutic areas	Neurology
Lead asset	ATH434 (iron redistributor)
Platform	Yes

Financial summary (AUD)	
Market cap	\$9.8M
Price	\$0.005
52wk hi	\$0.01
52wk lo	\$0.005
Avg vol (3m)	13.2M
Shares	2.4B
Cash	\$24.5M

<https://alteritytherapeutics.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
ATH434						Ph 2 in early-stage multiple system atrophy (MSA)
						Ph 2 biomarker study in advanced MSA
						Parkinson's work with Michael J. Fox Foundation
Catalysts	1Q'24	2Q'24	2H'24	Notes		
ATH434	X	X		Preliminary data from Ph 2 early-stage MSA trial		
			X	Primary completion Ph 2 early-stage MSA trial (full data)		
			X	Primary completion for the biomarker study in advanced MSA		



Amplia Therapeutics Ltd (ATX.AX)



SUMMARY & FOCUS AREAS

Amplia Therapeutics Limited is a clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. Amplia's pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
AMP945						Ongoing Ph 1/2a in pancreatic cancer (completed health vol.)
						IND-enabling studies in multiple solid tumors and IPF
AMP886						Ongoing work for this FAK / VEGFR3 / FLT3 inhibitor
Catalysts	1Q'24	2Q'24	2H'24	Notes		
AMP945	X			Initial clinical data from the ACCENT pancreatic cancer trial		
	X	X		Initiate Ph 2a portion of the ACCENT pancreatic cancer trial		

COMPANY CHEAT SHEET

Amplia Therapeutics was founded in 2000 as part of Cancer Therapeutics CRC and listed on the Australian Securities Exchange (ASX) in December 2013.

Therapeutic areas	Fibrosis; oncology
Lead asset	AMP945 (FAK inhibitor)
Platform	No

Financial summary (AUD)	
Market cap	\$9.8M
Price	\$0.08
52wk hi	\$0.12
52wk lo	\$0.06
Avg vol (3m)	35K
Shares	194M
Cash	\$5.7M

<https://www.ampliatx.com>



Anatara Lifesciences (ANR.AX)



SUMMARY & FOCUS AREAS

Anatara Lifesciences is developing evidence-based solutions for gastrointestinal diseases in humans and animals. Gastrointestinal ReProgramming (GaRP), the working title for Anatara's evidence-based complementary medicine, contains a special form of bromelain along with other components.

COMPANY CHEAT SHEET

Anatara Life Sciences was founded in 2010 and listed on the Australian Securities Exchange (ASX) in Oct 2014.

Therapeutic areas	Gastrointestinal
Lead asset	GaRP (bromelain combo)
Platform	No

Financial summary (AUD)	
Market cap	\$4.0M
Price	\$0.02
52wk hi	\$0.05
52wk lo	\$0.02
Avg vol (3m)	65.7K
Shares	168M
Cash	\$1.6M

<https://anataralifesciences.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
GaRP						Ongoing irritable bowel syndrome (IBS) Ph 2

Catalysts	1Q'24	2Q'24	2H'24	Notes
GaRP		X		Final results of Phase 2 IBS trial (Stage 2 completion)



Antisense Therapeutics (ANP.AX)



SUMMARY & FOCUS AREAS



Antisense Therapeutics is developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The company will rebrand as Percheron Therapeutics in 2024.

COMPANY CHEAT SHEET

Antisense Therapeutics was founded in 2000 and listed on the ASX in 2005. The company licenses its technology from Ionis Pharmaceuticals.

Therapeutic areas	Neuro; endo
Lead asset	ATL1102 (CD49d ASO)
Platform	No

Financial summary (AUD)	
Market cap	\$52.3M
Price	\$0.06
52wk hi	\$0.11
52wk lo	\$0.05
Avg vol (3m)	511K
Shares	902M
Cash	\$19.2M

<https://www.antisense.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
ATL1102						Ongoing Ph 2b in Duchenne muscular dystrophy (DMD)
						Eligible for Ph 2 in multiple sclerosis
ATL1103						Eligible for Ph 2 in acromegaly

Catalysts	1Q'24	2Q'24	2H'24	Notes
ATL1102	X			Complete recruitment in Ph 2b DMD trial
			X	Topline data for Ph 2b DMD trial and engagement with FDA
*Corporate		X	X	Rebrand to Percheron Therapeutics, increase BD/IR efforts



Argenica Therapeutics (AGN.AX)



SUMMARY & FOCUS AREAS

Argenica Therapeutics Limited is developing novel neuroprotective therapeutics to reduce brain damage as an early intervention for stroke. The technology is based on the work of Professor Bruno Meloni and Clinical Professor Neville Knuckey at the University of Western Australia and the Perron Institute for Neurological and Translational Science.



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
ARG-007						Ongoing Ph 2 trial in stroke
						Ongoing safety / tox work in hypoxic ischemic encephalopathy
						Ongoing early efficacy work in traumatic brain injury
Catalysts	1Q'24	2Q'24	2H'24	Notes		
ARG-007	X			Commence dosing in Ph 2 stroke trial		
		X		Initial safety review and enrollment update from Ph 2 trial		
			X	FDA pre-IND meeting and preparation for international Ph 2		

COMPANY CHEAT SHEET

Argenica was founded in 2019 and listed on the ASX in 2021. The technology comes from the University of Western Australia and the Perron Institute.

Therapeutic areas	Cardiovascular
Lead asset	ARG-007 (Arg-rich peptide)
Platform	No

Financial summary (AUD)	
Market cap	\$65.9M
Price	\$0.61
52wk hi	\$0.68
52wk lo	\$0.30
Avg vol (3m)	138K
Shares	99.2M
Cash	\$7.4M

<https://argenica.com.au/>



Arovella Therapeutics (ALA.AX)



SUMMARY & FOCUS AREAS

Arovella Therapeutics is focused on developing therapies to treat human disease, specifically oncology and conditions that impact the central nervous system. The company develops its existing products and looks to acquire additional platforms complimentary to the therapeutic areas of interest.

COMPANY CHEAT SHEET

Arovella was founded in 1999 listed on the Australian Securities Exchange (ASX) in 2005.

Therapeutic areas	Oncology; neuro
Lead asset	ALA-101 (CAR19-iNKT)
Platform	Yes

Financial summary (AUD)	
Market cap	\$123.8M
Price	\$0.13
52wk hi	\$0.16
52wk lo	\$0.02
Avg vol (3m)	2.4M
Shares	917M
Cash	\$7.2M

<https://www.arovella.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
ALA-101						CAR19-iNKT in CD19-expressing lymphomas
						Combination with onCARlytics (Imugene) in solid tumors
ALA-105						CLDN18.2-iNKT in CLDN18.2-expressing solid tumors
Catalysts	1Q'24	2Q'24	2H'24	Notes		
ALA-101	X	X		Complete IND-enabling activities for Ph 1		
	X	X	X	Initiate Ph 1 first-in-human trial in CD19+ blood cancers (2024)		
ALA-105	X	X	X	Initiate proof-of-concept testing for CLDN18.2-iNKT cells (2024)		



Avita Medical (AVH.AX)



SUMMARY & FOCUS AREAS

AVITA Medical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The company's FDA-approved RECELL® System technology platform treats patients with thermal burn wounds and full-thickness skin defects.

COMPANY CHEAT SHEET

Avita Medical was founded in 1999, listed on the Australian Securities Exchange (ASX) in 2005 and uplisted to the NASDAQ (RCEL) in 2012.

Therapeutic areas	Dermatology
Lead asset	RECELL (autologous cell tx)
Platform	Yes

Financial summary (AUD)	
Market cap	\$582.6M
Price	\$4.60
52wk hi	\$6.27
52wk lo	\$2.11
Avg vol (3m)	220K
Shares	128M
Cash	\$89.1M

<https://ir.avitamedical.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
RECELL						Initial FDA approval in 2018 for thermal burn wounds
						FDA expanded approval June 2023 includes full thickness burns
						Post-market study (TONE) for stable vitiligo lesions
Catalysts	1Q'24	2Q'24	2H'24	Notes		
RECELL	X			FDA PMA Supplement approval expected (May 30 action date)		
		X		Primary completion data for ongoing vitiligo study		
Corporate*	X	X	X	Revenue guidance: \$14.8-15.6M (Q1); \$78.5-84.5M (FY'24)		



Biotron Ltd (BIT.AX)



SUMMARY & FOCUS AREAS

Biotron is developing and commercializing a novel small molecule approach that has the potential to treat a number of serious viral diseases by targeting viroporin proteins, which are key to enabling the pathogenicity of a number of viruses. Biotron's proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins.



COMPANY CHEAT SHEET

Biotron was founded in 1999, listed on the Australian Securities Exchange (ASX) in 2001 and uplisted to the Pink Sheets (BITRF) in 2013.

Therapeutic areas	Antiviral
Lead asset	BIT225 (viroporin inh.)
Platform	Yes

Financial summary (AUD)	
Market cap	\$90.2M
Price	\$0.10
52wk hi	\$0.13
52wk lo	\$0.02
Avg vol (3m)	4.0M
Shares	902M
Cash	\$2.6M

<https://www.biotron.com.au>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
BIT225						Two ongoing Ph 2 trials in HIV-1
						One ongoing Ph 2 trial in SARS-CoV-2
*Platform						Four ongoing screening processes for HBV, HIV, and COVID

Catalysts	1Q'24	2Q'24	2H'24	Notes
	X	X		Primary readout for ongoing Ph 2 HIV trials
BIT225	X	X		Primary readout for ongoing Ph 2 SARS-CoV-2 trial
		X	X	BD and regulatory discussions (commensurate on Ph 2 success)



Botanix Pharmaceuticals (BOT.AX)



SUMMARY & FOCUS AREAS

Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product Sofpironium Bromide for the treatment of primary axillary hyperhidrosis. Three other clinical-stage programs have completed, or are currently undergoing Phase 2 studies, for dermatology and antimicrobial indications.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Sofdra						FDA issued Complete Response Letter in hyperhidrosis
BTX1503						Eligible to begin Ph 3 in moderate to severe acne
BTX1702						Completed Ph 1b/2 in rosacea

Catalysts	1Q'24	2Q'24	2H'24	Notes
Sofdra		X		Expected full FDA approval of Sofdra in hyperhidrosis
			X	Expected US launch of Sofdra in hyperhidrosis

COMPANY CHEAT SHEET

Botanix was founded in 1984, listed on the Australian Securities Exchange (ASX) in 1988 and uplisted to the Pink Sheets (BXPHE) in 2019.

Therapeutic areas	Dermatology
Lead asset	Sofdra (anticholinergic)
Platform	Yes

Financial summary (AUD)	
Market cap	\$272.2M
Price	\$0.19
52wk hi	\$0.21
52wk lo	\$0.06
Avg vol (3m)	3.4M
Shares	1.6B
Cash	\$20.3M

<https://botanixpharma.com>



Chimeric Therapeutics (CHM.AX)



SUMMARY & FOCUS AREAS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. The company is focused on the discovery, development and commercialization of the most innovative and promising cell therapies.



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
CHM2101						Ongoing Ph 1/2 trial in R/R GI cancers
CHM1101						Ongoing Ph 1a IIT and Ph 1b trial in glioblastoma
CHM0201						Completed Ph 1a IIT

Catalysts	1Q'24	2Q'24	2H'24	Notes
CHM1101	X	X		Potential topline results from Ph 1 trial (PCD Oct 2023)
CHM2101	X	X		Enrollment start of Ph 1/2 open label trial in R/R GI cancers

COMPANY CHEAT SHEET

Chimeric was founded in 2020 by current CEO Paul Hopper, listed on the ASX in 2021 and uplisted to the Pink Sheets (CHMMF) in 2022.

Therapeutic areas	Oncology
Lead asset	CHM2101 (anti-CD17 CART)
Platform	Yes

Financial summary (AUD)	
Market cap	\$24.0M
Price	\$0.03
52wk hi	\$0.09
52wk lo	\$0.03
Avg vol (3m)	4.0M
Shares	727M
Cash	\$4.6M

<https://chimerictherapeutics.com>



Clarity Pharmaceuticals (CU6.AX)



SUMMARY & FOCUS AREAS



Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation theranostic products, based on its SAR Technology platform. The SAR Technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products.

COMPANY CHEAT SHEET

Clarity Pharma was founded in 2010 with \$650K in seed capital. The company listed on the Australian Securities Exchange (ASX) in 2021.

Therapeutic areas	Oncology
Lead asset	SAR-bisPSMA (anti-PSMA)
Platform	Yes

Financial summary (AUD)	
Market cap	\$555.9M
Price	\$2.20
52wk hi	\$2.50
52wk lo	\$0.68
Avg vol (3m)	442K
Shares	262M
Cash	\$53.6M

<https://claritypharmaceuticals.com/>

Lead Pipeline*	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
SAR-bisPSMA						Ongoing Ph 1/2 trial (SECURE) in metastatic CRPC
SARTATE						Ongoing Ph 1/2 trial (CL04) in neuroblastoma
SAR-BBN						Ongoing Ph 1/2 trial (COMBAT) in metastatic CRPC

Catalysts	1Q'24	2Q'24	2H'24	Notes
SAR-bisPSMA	X	X		Initial data from Ph 1/2 COBRA study in PSMA prostate cancer
SARTATE	X	X		Potential initial data from Ph 1/2 DISCO trial in NETs
SAR-BBN		X		Primary completion of Ph 2 SABRE trial in PSMA- prostate canc

*Does not include products used as diagnostics, though there is overlap



Clinuvel Pharmaceuticals (CUV.AX)



SUMMARY & FOCUS AREAS

Clinuvel is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population. The company's Scenesse product is approved in most major geographies.

COMPANY CHEAT SHEET

Clinuvel was spun out of a university in 1987 with the tech licensed in 2001. The company was listed on the Australian Securities Exchange (ASX) in 2001.

Therapeutic areas	Specialty pharma
Lead asset	Scenesse (MC1R agonist)
Platform	No

Financial summary (AUD)	
Market cap	\$769.5M
Price	\$15.99
52wk hi	\$28.72
52wk lo	\$13.97
Avg vol (3m)	69.8K
Shares	50.1M
Cash	\$156.8M

<https://www.clinuvel.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Scenesse						Approved in erythropoietic protoporphyria (EPP) worldwide
						Ongoing Ph 2 trials in vitiligo, XP, and stroke
Prenumbra						Ongoing Ph 2 in arterial ischemic stroke

Catalysts	1Q'24	2Q'24	2H'24	Notes
Prenumbra	X			Ph 2 arterial ischemic stroke readout expected
	X	X		Ph 2 xeroderma pigmentosum primary completion and data
Scenesse	X	X	X	Variegate porphyria final results and EMA EPP guidance





SUMMARY & FOCUS AREAS

CSL is a leading global biotechnology company with a portfolio of medicines that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. CSL – including the three businesses, CSL Behring, CSL Seqirus and CSL Vifor – employs 32,000 people and provides products to patients in more than 100 countries.

COMPANY CHEAT SHEET

CSL Limited was established in 1916 as Commonwealth Serum Laboratories. It was listed on the Australian Securities Exchange (ASX) in 1994.

Therapeutic areas	Multiple
Lead asset	Multiple approved products
Platform	No

Financial summary (AUD)	
Market cap	\$137.5B
Price	\$289.17
52wk hi	\$314.28
52wk lo	\$228.65
Avg vol (3m)	707K
Shares	483M
Cash	\$1.6B

<https://www.csl.com>

Lead Pipeline*	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Garadacimab						Anti-FXIIa mAb completed Ph 3 for hereditary angioedema
Clazakizumab						Anti-IL-6 mAb in Ph 3 for chronic antibody-mediated rejection
CSL112						apoA-I in Ph 3 for reduction of MACE after MI

Catalysts*	1Q'24	2Q'24	2H'24	Notes
CSL112	X	X		Ph 3 topline results expected for acute myocardial infarction
Clazakizumab	X	X		Pivotal Ph 3 study startup and first patient enrollment
CSL964	X	X		Ph 3 topline results expected for treatment of acute GvHD

*Excludes marketed, biosimilar, and LCM products; Lead Pipeline includes non-partnered assets only



Cynata Therapeutics (CYP.AX)



SUMMARY & FOCUS AREAS

Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). Cynata's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs).

COMPANY CHEAT SHEET

Cynata was founded in 2011 with patents owned by the Wisconsin Alumni Research Foundation (WARF). The company was listed on the ASX in 2008.

Therapeutic areas	Multiple
Lead asset	CYP-004 (allogeneic iPSCs)
Platform	Yes

Financial summary (AUD)	
Market cap	\$24.3M
Price	\$0.13
52wk hi	\$0.36
52wk lo	\$0.11
Avg vol (3m)	50.5K
Shares	180M
Cash	\$14.4M

<https://www.cynata.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
CYP-004						Ongoing Ph 3 osteoarthritis trial (partnered program)
CYP-001						Ongoing Ph 2 trial in acute graft vs host disease (GvHD)
CYP-006TK						Ongoing Ph 1 trial in diabetic foot ulcers (DFUs)

Catalysts	1Q'24	2Q'24	2H'24	Notes
CYP-006TK	X			Expected topline results for Ph 1 DFU trial
CYP-001	X	X		Expected Ph 1 trial enrollment completes for renal transplant
			X	Expecting recruitment completion for Ph 2 in aGvHD



Dimerix Ltd (DXB.AX)



COMPANY CHEAT SHEET

Dimerix was founded in 2004 with lead product funded in 2014. The company was listed on the Australian Securities Exchange (ASX) in 2005.

Therapeutic areas	Nephrology
Lead asset	DMX-200 (CCR2 blocker)
Platform	Yes

Financial summary (AUD)	
Market cap	\$84.5M
Price	\$0.21
52wk hi	\$0.27
52wk lo	\$0.05
Avg vol (3m)	2.8M
Shares	433M
Cash	\$17.5M

<https://dimerix.com>

SUMMARY & FOCUS AREAS

Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. The company utilizes a scalable, proprietary platform technology called Receptor-HIT to identify and develop drugs in areas with an unmet need.



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
DMX-200						Ongoing Ph 3 trials for focal segmental glomerulosclerosis
						Ph 2-eligible in diabetic kidney disease
DMX-700						Preclinical program in chronic obstructive pulmonary disease

Catalysts	1Q'24	2Q'24	2H'24	Notes
DMX-200	X			Initial analysis from Part 1 of Ph 3 trial (ACTION3)
	X	X		Opening of additional sites in China for ACTION3



Firebrick Pharma (FRE.AX)



SUMMARY & FOCUS AREAS

Firebrick Pharma is an Australian pharmaceutical developer founded with the mission to develop a povidone-iodine nasal spray that targets viruses or bacteria responsible for respiratory infections. The product is approved as Nasodine and is now in life-cycle management development.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Nasodine						Completed two Ph 3 trials with mixed results in common cold
						Completed Ph 2 trial in clearance of SARS-CoV

Catalysts	1Q'24	2Q'24	2H'24	Notes
Nasodine	X	X	X	Sales expected to commence in undisclosed countries

COMPANY CHEAT SHEET

Firebrick Pharma was incorporated in 2012 and began trading on the Australian Securities Exchange (ASX) in 2022.

Therapeutic areas	Anti-infective
Lead asset	Nasodine (povidone-iodine)
Platform	No

Financial summary (AUD)	
Market cap	\$9.8M
Price	\$0.05
52wk hi	\$0.36
52wk lo	\$0.04
Avg vol (3m)	975K
Shares	178M
Cash	\$2.7M

<https://firebrickpharma.com/>



Hexima Ltd (HXL.AX)



SUMMARY & FOCUS AREAS

Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics. The company's lead asset, pezadeftide, was in development for onychomycosis.



COMPANY CHEAT SHEET

Hexima was founded in 1997 by current SVP Dr. Marilyn Anderson. The company was listed on the Australian Securities Exchange (ASX) in 2020.

Therapeutic areas	Anti-infective
Lead asset	Pezadeftide (antifungal)
Platform	No

Financial summary (AUD)	
Market cap	\$3.0M
Price	\$0.02
52wk hi	\$0.02
52wk lo	\$0.01
Avg vol (3m)	12.1K
Shares	167M
Cash	\$2.0M

<https://hexima.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Pezadeftide						Ph 2 trial in onychomycosis failed to meet endpoints

Catalysts	1Q'24	2Q'24	2H'24	Notes
Pezadeftide	X	X	X	Ongoing business development and licensing discussions with worldwide third parties



Immutep Ltd (IMM.AX)



SUMMARY & FOCUS AREAS

Immutep is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) Immunotherapy for cancer and autoimmune diseases. The company has an internal pipeline and also outlicensed oncology and autoimmune assets to Novartis and GSK, respectively.

COMPANY CHEAT SHEET

Immutep (nee Prima BioMed) was founded in 2001, listed on the Australian Securities Exchange (ASX) in 1988 and uplisted to the NASDAQ in 2012.

Therapeutic areas	Oncology; I&I
Lead asset	IMP321 (LAG-3 Ig)
Platform	Yes

Financial summary (AUD)	
Market cap	\$451.8M
Price	\$0.37
52wk hi	\$0.42
52wk lo	\$0.23
Avg vol (3m)	1.2M
Shares	1.2B
Cash	\$110.1M

<https://www.immutep.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
IMP321						Two Ph 3 trials in mBC/TNBC and 1L HNSCC
						Ph 2 trials in 1L NSCLC and 2L NSCLC / HNSCC (+pembro)
						Multiple partnered Ph 1 trials in a variety of tumor types
Catalysts	1Q'24	2Q'24	2H'24	Notes		
IMP321	X	X		Topline data from Ph 2b HNSCC trial (TACTI-003)		
		X	X	Trial updates from TACTI-004, INSIGHT-003/-005, AIPAC-003		
IMP761	X	X		IND filing and first clinical initiation in autoimmune disease		



Imugene Ltd (IMU.AX)



COMPANY CHEAT SHEET

Imugene was founded in 2012 by Paul Hopper (currently at [Chimeric](#)) with the company going public on the ASX in 2013.

Therapeutic areas	Oncology
Lead asset	HER-Vaxx (anti-HER2 vaccine)
Platform	Yes

Financial summary (AUD)	
Market cap	\$752.8M
Price	\$0.11
52wk hi	\$0.17
52wk lo	\$0.04
Avg vol (3m)	55.5M
Shares	7.2B
Cash	\$163.4M

<https://www.imugene.com/>

SUMMARY & FOCUS AREAS

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. The company's onCARlytics (CF33-CD19) platform is a combination immunotherapy utilizing the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells.



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
HER-Vaxx						Anti-HER2 vaccine having completed a Ph 2 trial
B-Vaxx						Ongoing Ph 2 trial for this anti-HER2 vaccine
Azer-cel						Ongoing Ph 1b trial for this allogeneic CAR-T therapy

Catalysts	1Q'24	2Q'24	2H'24	Notes
PD1-Vaxx	X			First patient in for the Ph 2 MSI-hi cohort in CRC
OnCARlytics	X	X		First patient in (Cohort 1 and 2) for intrathecal/IV combo study
Azer-cel		X	X	Ph 1b enrollment complete and initiate pivotal Ph 2 in DLBCL



Invion Ltd (IVX.AX)



SUMMARY & FOCUS AREAS

Invion is an Australian life-sciences company focused on transforming Photodynamic Therapy (PDT) for novel and effective treatments for cancer. The company is leading the global research and development of the Photosoft™ technology and holds the Australia and New Zealand license and distribution rights.

COMPANY CHEAT SHEET

Invion Group was founded in 2000 and listed on the Australian Securities Exchange (ASX) in 2010.

Therapeutic areas	Oncology
Lead asset	INV043 (photodynamic tx)
Platform	No

Financial summary (AUD)	
Market cap	\$32.1M
Price	\$0.01
52wk hi	\$0.01
52wk lo	\$0.01
Avg vol (3m)	1.1M
Shares	6.4B
Cash	\$3.4M

<https://inviongroup.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
INV043						Preparing for Ph 1/2 in non-melanoma skin cancers (topical)
						Preparing for Ph 1b/2 in anogenital cancers (topical)
						Preparing for Ph 1 in solid tumors (IV)
Catalysts	1Q'24	2Q'24	2H'24	Notes		
INV043	X	X		Recruitment open for adaptive Ph 1 trial in skin cancer		
			X	Initiate Ph 1 trial in solid tumors		
			X	Initiate Ph 1b/2 trial in anogenital cancers		



Island Pharmaceuticals (ILA.AX)



SUMMARY & FOCUS AREAS

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company's lead asset, ISLA-101, was initially developed by its wholly owned subsidiary, Isla Pharmaceuticals. The asset may be eligible for a Priority Review Voucher, if approved.

COMPANY CHEAT SHEET

Island Pharma was founded in 2020 to absorb the assets from Isla Pharma (founded 2017). The company was listed on the ASX in 2021.

Therapeutic areas	Anti-infective
Lead asset	ISLA-101 (oral antiviral)
Platform	No

Financial summary (AUD)	
Market cap	\$6.9M
Price	\$0.09
52wk hi	\$0.19
52wk lo	\$0.06
Avg vol (3m)	45.0K
Shares	81.3M
Cash	\$2.1M

<https://www.islandpharmaceuticals.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
ISLA-101						Ongoing Ph 1 SAD trial (prev. completed Ph 2 oncology trials)

Catalysts	1Q'24	2Q'24	2H'24	Notes
	X			Screening commences for Cohort 3 of SAD trial
ISLA-101	X	X		Final results for Ph 1 SAD trial
			X	Initiate Ph 2a trial (PEACH) for prophylactic antiviral treatment



LTR Pharma (LTP.AX)



SUMMARY & FOCUS AREAS

LTR Pharma is focused on holistically improving men's health, physically and mentally, through the commercialization of an innovative intranasal spray treatment for Erectile Dysfunction (ED). The company is aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

COMPANY CHEAT SHEET

LTR Pharma was a recent (December 2023) IPO on the Australian Stock Exchange (ASX).

Therapeutic areas	Men's health
Lead asset	SPONTAN (PDE5 inhibitor)
Platform	No

Financial summary (AUD)	
Market cap	\$44.6M
Price	\$0.33
52wk hi	\$0.41
52wk lo	\$0.25
Avg vol (3m)	1.2M
Shares	135M
Cash	\$7.0M

<https://www.ltrpharma.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
SPONTAN						Preparing pivotal study via 505(b)(2) pathway

Catalysts	1Q'24	2Q'24	2H'24	Notes
SPONTAN		X		Completion of bioequivalence study (mid-2024)
		X	X	Commencing FDA and TGA regulatory meetings
			X	US FDA NDA filing via 505(b)(2) pathway



Mayne Pharma Group (MYX.AX)



SUMMARY & FOCUS AREAS

Mayne Pharma is a specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. The company has developed new oral drug delivery systems and focuses on the therapeutic areas of women's health, infectious disease, pain, and dermatology.

COMPANY CHEAT SHEET

FH Faulding & Co was founded in 1845 and merged with Mayne Group in 2001. The company was listed on the ASX in 2007.

Therapeutic areas	Multiple
Lead asset	Multiple marketed products
Platform	Yes

Financial summary (AUD)	
Market cap	\$455.1M
Price	\$5.57
52wk hi	\$6.42
52wk lo	\$2.68
Avg vol (3m)	393K
Shares	85.1M
Cash	\$220.1M

<https://www.maynepharma.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Bijuva						Approved therapy for mod / sev vasomotor symptoms
Imvexxy						Approved therapy for mod / sev dyspareunia
Wynzora						Approved therapy for plaque psoriasis in the US

Catalysts	1Q'24	2Q'24	2H'24	Notes
Bijuva	X	X		Launch of Bijuva low strength formulation
*Dermatology	X	X	X	Ongoing BD, including partnerships, M&A, and licensing
*Company	X	X		Expecting positive EBITDA in FY'24 (July '23 - June '24)



Mesoblast Ltd (MSB.AX)



SUMMARY & FOCUS AREAS

Mesoblast is using its proprietary technology platform to develop and commercialize allogeneic mesenchymal lineage cells to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role. The company's therapeutics respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.

COMPANY CHEAT SHEET

Mesoblast was founded by its current CEO Silviu Itescu in 2004. The company listed on the ASX in 2004 and uplisted to NASDAQ in 2006.

Therapeutic areas	Inflammation
Lead asset	Remestemcel-L (allogeneic cell tx)
Platform	Yes

Financial summary (AUD)	
Market cap	\$244.6M
Price	\$0.28
52wk hi	\$1.43
52wk lo	\$0.27
Avg vol (3m)	3.4M
Shares	858M
Cash	\$141.1M

<https://www.mesoblast.com/>



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Remestemcel						Completed Ph 3 in pediatric SR-aGVHD (adult trial planned)
Rexlemestrocel						Completed one of two Ph 3 trials in chronic low back pain
						Completed one of two Ph 3 trials in HFrEF Class II/III

Catalysts	1Q'24	2Q'24	2H'24	Notes
Remestemcel	X	X		Submit protocol to FDA and begin enrolling Ph 3 in SA-aGVHD
	X			Initiate enrollment for second Ph 3 in back pain
Rexlemestrocel	X			Updates from FDA meeting via RMAT for HFrEF Ph 3 plans



MGC Pharmaceuticals (MXC.AX)



SUMMARY & FOCUS AREAS

MGC Pharma is a next-generation pharmaceutical company supplying plant-inspired medication (“phytomedicine”) and novel product candidates for adults and children. The company aims to “gently and effectively” treat diseases across a range of therapeutic areas.

COMPANY CHEAT SHEET

MGC Pharma was founded in 2014 by current CEO Roby Zomer, with current shares listed on the Australian Securities Exchange (ASX) in 2016.

Therapeutic areas	Neuro; oncology
Lead asset	CimetrA (curcumin combo)
Platform	No

Financial summary (AUD)	
Market cap	\$19.3M
Price	\$0.47
52wk hi	\$2.00
52wk lo	\$0.01
Avg vol (3m)	19.6K
Shares	43.9M
Cash	\$8.3M

<https://mgcpharma.co.uk>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
CimetrA						Ongoing Ph 2b in cytokine storm associated with COVID
CannEpil						Ongoing Ph 2b of cannabinoid combo for refractory epilepsy
CogniCann						Completed Ph 2 trial in Alzheimer’s

Catalysts	1Q’24	2Q’24	2H’24	Notes
CannEpil	X	X		Continue opening sites in ongoing Ph 2b epilepsy trial
CimetrA	X	X		IND submission planned for additional US trial
			X	Completion of ongoing Ph 2b in COVID



Neuren Pharmaceuticals (NEU.AX)



SUMMARY & FOCUS AREAS

Neuren Pharmaceuticals is developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and are characterized by impaired connections and signaling between brain cells. Neuren's partner, Acadia Pharmaceuticals (NASDAQ:ACAD) holds a worldwide exclusive license from Neuren for trofinetide.

COMPANY CHEAT SHEET

Neuren was founded in 2001 and listed on the Australian Securities Exchange (ASX) in 2005. The company licensed trofinetide to Acadia in 2018.

Therapeutic areas	Neurology
Lead asset	Daybue (GPE agonist)
Platform	No

Financial summary (AUD)	
Market cap	\$3.1B
Price	\$23.58
52wk hi	\$25.95
52wk lo	\$6.72
Avg vol (3m)	573K
Shares	130M
Cash	\$230.4M

<https://www.neurenpharma.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Daybue						Approved by FDA Mar 2023 for Rett Syndrome
NNZ-2591						Completed Ph 2 trial in Phelan-McDermid syndrome
						Ongoing Ph 2s in Angelman, Pitt Hopkins, and Prader-Willi

Catalysts	1Q'24	2Q'24	2H'24	Notes
NNZ-2591		X		Topline results from Ph 2 trial in Pitt Hopkins syndrome
			X	Topline results from Ph 2 trial in Angelman syndrome
Daybue	X	X	X	Additional updates and royalties from Acadia



Neuroscientific Biopharma (NSB.AX)



SUMMARY & FOCUS AREAS

Neuroscientific Biopharmaceuticals is an Australian company developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. The company's products are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).

COMPANY CHEAT SHEET

Neuroscientific Biopharma was incorporated in 2002 and listed on the Australian Securities Exchange (ASX) in 2018.

Therapeutic areas	Neuro; ophtho
Lead asset	EmtinB (LRP-1 modulator)
Platform	Yes

Financial summary (AUD)	
Market cap	\$5.6M
Price	\$0.04
52wk hi	\$0.14
52wk lo	\$0.04
Avg vol (3m)	61.5K
Shares	145M
Cash	\$3.9M

<https://neuroscientific.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
EmtinB						Finalizing pre-IND for Ph 1 trial in ophthalmological indications
						Preclinical safety and toxicology work in non-human primates
						Preclinical in vitro work in multiple sclerosis
Catalysts	1Q'24	2Q'24	2H'24	Notes		
EmtinB	X			Lodge pre-IND Type B meeting request with the FDA		
		X		Complete ocular safety and 13wk GLP tox IND-enabling studies		
			X	Initiate Ph 1 Ocular clinical trial (expected Q3)		



Neurotech International (NTI.AX)



SUMMARY & FOCUS AREAS

Neurotech is a clinical-stage biopharmaceutical development company focused predominately on pediatric neurological disorders. The company is expanding its biopharma pipeline while also offering Mente, a personalized neurofeedback therapy for those on the autism spectrum.

COMPANY CHEAT SHEET

Neurotech International was incorporated and listed on the Australian Securities Exchange (ASX) in 2016.

Therapeutic areas	Neurology
Lead asset	NTI164 (cannabinoids)
Platform	No

Financial summary (AUD)	
Market cap	\$66.9M
Price	\$0.08
52wk hi	\$0.09
52wk lo	\$0.03
Avg vol (3m)	602K
Shares	891M
Cash	\$15.0M

<https://neurotechinternational.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
NTI164						Ongoing Ph 2/3 trial (NTIASD2) in autism spectrum disorder
						Ongoing Ph 1/2 trial in Rett syndrome
						Ph 1/2-ready in cerebral palsy and PANDAS
Catalysts	1Q'24	2Q'24	2H'24	Notes		
NTI164	X			Top line results expected for Ph 2/3 autism trial (NTIASD2)		
	X			Top line results expected for Ph 1/2 Rett syndrome trial		
		X	X	Meetings with TGA and FDA for next phase of clinical dev		



Noxopharm Ltd (NOX.AX)



SUMMARY & FOCUS AREAS

Noxopharm Limited is an Australian biotech company discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines. The company has unique proprietary technology aimed at making mRNA vaccines safer to take by reducing side effects while reducing manufacturing costs for vaccine producers.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Veyonda						Completed four Ph 1 and Ph 2 trials; ongoing Ph 1 basket
CRO-67						Chroma platform-produced molecule in pancreatic cancer
SOF-VAC						Sofra platform-produced adjuvant for mRNA vaccines

Catalysts	1Q'24	2Q'24	2H'24	Notes
Veyonda	X	X	X	Ph 1 IONIC trial (+Opdivo) additional readouts expected
CRO-67	X	X	X	Continue IND-enabling preclinical work with UNSW
SOF-VAC	X	X	X	Continue preclinical work and business development

COMPANY CHEAT SHEET

Noxopharm was founded in 2015 and listed on the ASX in 2016. Its drug discovery subsidiary Pharmorage was founded in 2020.

Therapeutic areas	Oncology; I&I
Lead asset	Veyonda (STING inhibitor)
Platform	Yes

Financial summary (AUD)	
Market cap	\$23.4M
Price	\$0.08
52wk hi	\$0.17
52wk lo	\$0.03
Avg vol (3m)	391K
Shares	292M
Cash	\$14.0M

<https://www.noxopharm.com/>



Nyrada Inc (NYR.AX)



SUMMARY & FOCUS AREAS

Nyrada is a drug discovery and development company, specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The company's drug development programs focus on areas of substantial unmet clinical need where few if any, effective or well-tolerated therapies exist.

COMPANY CHEAT SHEET

Nyrada was founded in 2017 by current non-exec director Dr. Ian Dixon. The company was listed on the Australian Securities Exchange (ASX) in 2020.

Therapeutic areas	Neurology
Lead asset	NYX-BI03 (TRPC 3/6/7 inh.)
Platform	Yes

Financial summary (AUD)	
Market cap	\$3.3M
Price	\$0.02
52wk hi	\$0.17
52wk lo	\$0.02
Avg vol (3m)	75.1K
Shares	156M
Cash	\$5.5M

<https://www.nyrada.com>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
NYX-BI03						Ongoing preclinical IND-enabling work for brain injury
Oral PCSK9						Setback in preclinical GLP study, will not enter the clinic

Catalysts	1Q'24	2Q'24	2H'24	Notes
NYX-BI03	X	X		Finalize IND-enabling studies and commence FDA outreach
			X	Initiate Ph 1 trial in brain injury (TBI, concussion, and stroke)
Corporate*	X	X	X	Ongoing cost-management, including non-dilutive funding



Opthea Ltd (OPT.AX)



SUMMARY & FOCUS AREAS

Opthea is committed to improving vision in patients suffering from retinal eye diseases. The company's lead asset has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases.

COMPANY CHEAT SHEET

Opthea was founded in 1984 by current CIO Dr. Megan Baldwin. The company listed on the ASX in 1991 and uplisted to the NASDAQ in 2016.

Therapeutic areas	Ophthalmology
Lead asset	Sozinibercept (VEGF-C/D trap)
Platform	No

Financial summary (AUD)	
Market cap	\$328.1M
Price	\$0.51
52wk hi	\$1.03
52wk lo	\$0.31
Avg vol (3m)	454K
Shares	663M
Cash	\$229.3M

<https://ir.opthea.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Sozinibercept						Ongoing Ph 3 trial (COAST) in wet AMD with Byooviz
						Ongoing Ph 3 trial (ShORe) in wet AMD with Eylea

Catalysts	1Q'24	2Q'24	2H'24	Notes
Sozinibercept	X			Enrollment completion expected for Ph 3 COAST trial
		X		Enrollment completion expected for Ph 3 ShORe trial



Orthocell Ltd (OCC.AX)



SUMMARY & FOCUS AREAS

Orthocell is a regenerative medicine company dedicated to the development of breakthrough products for the treatment of musculoskeletal disorders. The company utilizes its CelGro™ platform of collagen medical devices to augment surgical repair of bone and soft tissue.

COMPANY CHEAT SHEET

Orthocell was founded by current Managing Director Paul Anderson and listed on the Australian Securities Exchange (ASX) in August 2014.

Therapeutic areas	Orthopedics
Lead asset	Multiple marketed products
Platform	Yes

Financial summary (AUD)	
Market cap	\$79.7M
Price	\$0.40
52wk hi	\$0.46
52wk lo	\$0.32
Avg vol (3m)	156K
Shares	199M
Cash	\$22.3M

<https://orthocell.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Striate+						Collagen membrane for dental applications approved WW
CelGro						Ph 3-ready collagen medical device for nerve repair
OrthoATI						Completed pivotal Ph 2b tendon cell therapy for tennis elbow

Catalysts	1Q'24	2Q'24	2H'24	Notes
OrthoATI	X	X	X	Ongoing BD discussions following successful Ph 2b
Remplir	X			Completion of pivotal Remplir nerve repair study



Paradigm Biopharma (PAR.AX)



SUMMARY & FOCUS AREAS

Paradigm Pharmaceuticals Ltd is a global biopharmaceutical company driven to discover, develop, and deliver pharmaceutical therapies to improve patients' health and quality of life. The company is a commercially-focused drug development company that believes identifying and transforming underutilized molecules is the most optimal path to addressing an unmet need.

COMPANY CHEAT SHEET

Paradigm Biopharma was founded in 2014 and listed on the Australian Securities Exchange (ASX) in August 2015.

Therapeutic areas	Orthopedics
Lead asset	PPS / Zilusol (anti-inflammatory)
Platform	Yes

Financial summary (AUD)	
Market cap	\$135.3M
Price	\$0.40
52wk hi	\$1.73
52wk lo	\$0.36
Avg vol (3m)	1.1M
Shares	351M
Cash	\$69.4M

<https://paradigmbiopharma.com/>



Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
PPS / Zilusol						Ongoing Ph 3 trial in knee osteoarthritis
						Ongoing Ph 2 trials in mucopolysaccharidosis (MPS) VI

Catalysts	1Q'24	2Q'24	2H'24	Notes
PPS / Zilusol	X	X		Preparedness meetings with FDA and TGA on next steps
	X	X		Topline readout for Ph 2 trial in MPS IV
			X	Initiate pivotal Ph 3 in OA worldwide



Patrys Ltd (PAB.AX)



SUMMARY & FOCUS AREAS

Patrys listed on the Australian Securities Exchange (ASX) in 2007 to develop new antibody therapies for the treatment of cancer. In 2016, Patrys secured an exclusive, worldwide license from Yale University for the use of deoxymab antibodies as human therapeutic agents for treatment and management of cancer.

COMPANY CHEAT SHEET

Patrys was founded in 2006 and listed on the Australian Securities Exchange (ASX) in 2007 with its original antibody therapies for cancer.

Therapeutic areas	Oncology
Lead asset	PAT-DX1 (anti-DDR mAb)
Platform	Yes

Financial summary (AUD)	
Market cap	\$16.5M
Price	\$0.01
52wk hi	\$0.03
52wk lo	\$0.01
Avg vol (3m)	1.4M
Shares	2.1B
Cash	\$5.3M

<https://patrys.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
PAT-DX1						Finalizing scale up for first-in-human Ph 1 trial
PAT-DX1-NP						Nanoparticle payload version of PAT-DX1
PAT-DX3						Full-sized mAb version of PAT-DX1 targeting DDR

Catalysts	1Q'24	2Q'24	2H'24	Notes
PAT-DX1	X			New production run of antibody manufacturing
			X	Initiation of Ph 1 dose escalation trial in solid tumors
Corporate*	X	X	X	Ongoing BD talks, including IITs for Ph 2 indications



Pharmaust Ltd (PAA.AX)



SUMMARY & FOCUS AREAS



PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specializes in repurposing marketed drugs. The company recently voluntarily liquidated its subsidiary, Epichem, a contract medicinal chemistry company.

COMPANY CHEAT SHEET

PharmAust Ltd was founded in 2000 and listed on the ASX in October 2001. The company is currently revenue-generating.

Therapeutic areas	Multiple
Lead asset	Monepantel (mTOR inhibitor)
Platform	No

Financial summary (AUD)	
Market cap	\$50.1M
Price	\$0.13
52wk hi	\$0.14
52wk lo	\$0.07
Avg vol (3m)	370K
Shares	385M
Cash	\$9.7M

<https://www.pharmaust.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Monepantel						Marketed for parasite infections in food chain animals
						Completed Ph 1 trial in solid tumors (human)
						Ongoing Ph 1 trial in motor neuron disease (MND)
Catalysts	1Q'24	2Q'24	2H'24	Notes		
Monepantel	X			Final topline results expected for Ph 1 trial in MND		
	X			FDA pre-IND meeting for Ph 2/3 in MND (Feb 13, 2024)		
	X	X		IND submission and initiation of Ph 2/3 trial in MND		



Prescient Therapeutics (PTX.AX)



SUMMARY & FOCUS AREAS

Prescient Therapeutics is a clinical-stage biotech company developing personalized medicine approaches to cancer, including targeted and cellular therapies, emanating from Yale, Penn, Oxford and Moffitt. Prescient owns the exclusive rights to two next-generation cell therapy platform technologies, OmniCAR and CellPryme.

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
PTX-200						Completed Ph 2a in HER-2 neg BC and Ph 1b in plat. res. OC
PTX-100						Ongoing Ph 1b trial in T cell lymphomas
CellPryme-M						Late preclinical work for this T / NK cell modifier

Catalysts	1Q'24	2Q'24	2H'24	Notes
PTX-100	X	X		FDA meeting regarding Ph 2 study design and approval
		X	X	Initiate registrational Ph 2 study in T cell lymphoma (mid-2024)
PTX-200		X		"Go / no go" decision on further progress

COMPANY CHEAT SHEET

Prescient was founded in 2014 as a combination of Pathway Oncology and AKTivate Therapeutics and reverse merged on the ASX in December 2014.

Therapeutic areas	Oncology
Lead asset	PTX-200 (Akt inhibitor)
Platform	Yes

Financial summary (AUD)	
Market cap	\$49.9M
Price	\$0.06
52wk hi	\$0.14
52wk lo	\$0.05
Avg vol (3m)	991K
Shares	805M
Cash	\$21.1M

<https://ptxtherapeutics.com/>



PYC Therapeutics (PYC.AX)



SUMMARY & FOCUS AREAS

PYC Therapeutics is a drug-development company offering a new generation of RNA therapeutics to meet unmet need in disease. The company has RNA targeted therapeutics design capabilities which are supported by its revolutionary delivery technology based on Cell Penetrating Peptides (CPPs) to overcome the 'delivery challenge' in genomic therapies.

COMPANY CHEAT SHEET

PYC was founded in 2001 and listed on the ASX in 2005 by current CSO Dr. Sue Fletcher, whose research also underpins Sarepta Therapeutics (NASDAQ:SRPT).

Therapeutic areas	Multiple
Lead asset	VP-001 (CNOT3 regulator)
Platform	Yes

Financial summary (AUD)	
Market cap	\$336.0M
Price	\$0.09
52wk hi	\$0.12
52wk lo	\$0.05
Avg vol (3m)	1.8M
Shares	3.7B
Cash	\$21.0M

<https://pyctx.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
VP-001						Ongoing Ph 1 trial in retinitis pigmentosa type 11 (RP11)
PYC-001						Ph 1 OPA1 RNA for autosomal dominant optic atrophy (ADOA)
PYC-002						SHANK3 RNA for Phelan-McDermid syndrome

Catalysts	1Q'24	2Q'24	2H'24	Notes
PYC-001	X	X		Opening of enrollment in Ph 1 trial in ADOA
		X	X	Top line data for Ph 1 trial in RP11 (mid-2024)
VP-001			X	Planned start for Ph 2 trial in RP11



Race Oncology (RAC.AX)



SUMMARY & FOCUS AREAS

Race Oncology is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. The company hopes to address the high unmet need of patients across multiple oncology indications by making use of the unique mechanisms of action of its lead drug, bisantrene.

COMPANY CHEAT SHEET

Race Oncology was founded on advancing technology from the 1970s. The company listed on the Australian Securities Exchange (ASX) in July 2016.

Therapeutic areas	Oncology
Lead asset	Bisantrene (FTO inhibitor)
Platform	No

Financial summary (AUD)	
Market cap	\$132.9M
Price	\$0.81
52wk hi	\$2.34
52wk lo	\$0.75
Avg vol (3m)	144K
Shares	164M
Cash	\$17.8M

<https://raceoncology.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
Bisantrene						Ongoing Ph 2 trial in AML with chemo + venetoclax
						Ongoing Ph 1b/2a in mBC with chemo
RC220						Progressing IND-enabling studies for “new” bisantrene (IV)

Catalysts	1Q'24	2Q'24	2H'24	Notes
Bisantrene	X	X		Final patient enrolled and clinical update from Ph 2 AML trial
	X	X		Finalizing cGMP batch and IND-enabling data package
RC220			X	Initiate Ph 1a/b trial in solid tumors



Radiopharm Theranostics (RAD.AX)



SUMMARY & FOCUS AREAS

Radiopharm Theranostics has the ambition to become a recognized leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. The company's technology allows for potential combination of imaging and therapeutic properties for drug assets.



COMPANY CHEAT SHEET

Radiopharm Theranostics was founded by current Exec Chair Paul Hopper and listed on the Australian Securities Exchange (ASX) in 2021.

Therapeutic areas	Oncology
Lead asset	RAD204 (PD-L1 nano-mAb)
Platform	Yes

Financial summary (AUD)	
Market cap	\$33.6M
Price	\$0.09
52wk hi	\$0.22
52wk lo	\$0.06
Avg vol (3m)	245K
Shares	373M
Cash	\$10.6M

<https://www.radiopharmtheranostics.com>

Lead Pipeline*	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
RAD204						Ongoing Ph 1 PD-L1 nano-mAb in NSCLC
RAD202						Ph 1-ready HER2 nano-mAb in breast and gastric cancers
RAD502						Received ODD and RPDD designations from FDA in Sep 2022

Catalysts*	1Q'24	2Q'24	2H'24	Notes
RAD204	X			First patient dosed in Ph 1 for NSCLC
RAD202	X			First patient enrollment expected in Ph 1 for breast / gastric

*Does not include imaging-only trials and assets



Recce Pharmaceuticals (RCE.AX)



SUMMARY & FOCUS AREAS

Recce Pharmaceuticals Ltd is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs. The proprietary new class of anti-infectives is designed to work against viruses and antibiotic-resistant bacteria.

COMPANY CHEAT SHEET

Recce Pharma was founded in 2007 and listed on the Australian Securities Exchange (ASX) in January 2016.

Therapeutic areas	Anti-infective
Lead asset	R327 (ATP inhibitor)
Platform	No

Financial summary (AUD)	
Market cap	\$97.8M
Price	\$0.50
52wk hi	\$0.79
52wk lo	\$0.42
Avg vol (3m)	99.9K
Shares	204M
Cash	\$63.2M

<https://www.recce.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
R327-002/3						Multiple Ph 2s of IV formulation for UTIs and early sepsis
R327-101/2						Multiple Ph 2s of topical form. for infected wounds and DFUs
R327-001						Ongoing Ph 1 trial of IV formulation for life threatening sepsis

Catalysts	1Q'24	2Q'24	2H'24	Notes
R327-003	X			Topline readout for Ph 2 trial in UTI/urosepsis
R327-002		X	X	Topline readout for Ph 2 trial in sepsis (mid-2024)
R327-002/3			X	Initiate Ph 3s in UTI/urosepsis and sepsis



Starpharma Holdings Ltd (SPL.AX)



SUMMARY & FOCUS AREAS

Starpharma Holdings Limited is a world leader in dendrimer technology for medical applications. The company's technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules, which it uses to develop novel therapeutics and to improve the performance of existing pharmaceuticals.

COMPANY CHEAT SHEET

Founded in 1996, Starpharma listed on the Australian Securities Exchange (ASX) in 2000.

Therapeutic areas	Multiple
Lead asset	Multiple marketed products
Platform	Yes

Financial summary (AUD)	
Market cap	\$63.8M
Price	\$0.15
52wk hi	\$0.71
52wk lo	\$0.12
Avg vol (3m)	920K
Shares	412M
Cash	\$42.8M

<https://starpharma.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
DEP caba						Completed Ph 2 trial of DEP cabazitaxel in solid tumors
DEP irino						Ongoing Ph 2s of DEP irinotecan in solid tumors (2 complete)
DEP doce						Ongoing Ph 2 trial of DEP docetaxel in solid tumors

Catalysts	1Q'24	2Q'24	2H'24	Notes
DEP irino	X	X		Report additional results from ongoing Ph 2s in solid tumors
DEP doce	X	X		Report additional results from ongoing Ph 2s in solid tumors
*Corporate	X	X	X	Progress ongoing licensing and partnership discussions



Syntara Ltd (SYN.AX)



SUMMARY & FOCUS AREAS



Syntara (formerly Pharmaxis) is a clinical-stage drug development company targeting extracellular matrix dysfunction, with expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

COMPANY CHEAT SHEET

Syntara (formerly Pharmaxis) was established in 1998 and listed on the Australian Securities Exchange (ASX) in November 2003.

Therapeutic areas	I&I; fibrosis
Lead asset	SNT-5505 (LOX(L) inhibitor)
Platform	Yes

Financial summary (AUD)	
Market cap	\$14.1M
Price	\$0.02
52wk hi	\$0.03
52wk lo	\$0.02
Avg vol (3m)	2.1M
Shares	831M
Cash	\$15.6M

<https://syntaratx.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
SNT-5505						Ongoing Ph 2 study in myelofibrosis (MF)
SNT-4728						Ongoing Ph 2 in iRBD / neuroinflammation (SSAO inh.)
SNT-5382						Ph 1c-ready pan-LOX inhibitor in scar prevention

Catalysts	1Q'24	2Q'24	2H'24	Notes
SNT-5328	X			Initiate enrollment for Ph 1c trial in scar prevention
SNT-5505	X	X		Initiate enrollment for Ph 1/2 trial in myelodysplastic syndrome
			X	Interim 6mo data for ongoing Ph 2 trial in MF



Telix Pharmaceuticals (TLX.AX)



SUMMARY & FOCUS AREAS

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (“theranostic”) products using targeted radiation. Telix has received global regulatory approvals from the Australian TGA, the US FDA, and Health Canada for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide.

COMPANY CHEAT SHEET

Telix Pharma was founded in 2015 and listed on the ASX in November 2017. The company plans to uplist to the NASDAQ in 2024.

Therapeutic areas	Oncology
Lead asset	TLX591 (anti-PSMA mAb)
Platform	No

Financial summary (AUD)	
Market cap	\$3.5B
Price	\$10.72
52wk hi	\$12.79
52wk lo	\$5.83
Avg vol (3m)	955K
Shares	323M
Cash	\$137.4M

Lead Pipeline*	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
TLX591						Multiple ongoing trials including a Ph 3 in prostate cancer
TLX250						Ongoing Ph 2 IITs for this anti-CAIX mAb in RCC
TLX101						Ongoing Ph 1/2s for this LAT-1 small molecule in glioblastoma

Catalysts*	1Q'24	2Q'24	2H'24	Notes
TLX300	X			Initiate Ph 1 trial in soft tissue sarcoma (anti-PDGFRa)
TLX66	X	X		Initiate Ph 2 trial for bone marrow conditioning (anti-CD66)
TLX250			X	Topline data expected for Ph 2 IIT OPALESCENCE in RCC

*Does not include diagnostic-only trials and assets

<https://telixpharma.com/>



Tissue Repair Ltd (TRP.AX)



SUMMARY & FOCUS AREAS

Tissue Repair is a clinical stage biopharmaceutical company developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies. The company's Glucoprime platform technology is delivered topically.

COMPANY CHEAT SHEET

TR Therapeutics was founded in 2012 to combine Novogen Research Pty Ltd and Glycotex, Inc. The company was listed on the ASX in November 2021.

Therapeutic areas	Dermatology
Lead asset	TR987 (Dectin-1 activator)
Platform	Yes

Financial summary (AUD)	
Market cap	\$14.5M
Price	\$0.24
52wk hi	\$0.35
52wk lo	\$0.20
Avg vol (3m)	23.0K
Shares	60.5M
Cash	\$20.5M

<https://tissuerepair.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
TR987						Completed two Ph 2b trials in aesthetics and chronic wounds

Catalysts	1Q'24	2Q'24	2H'24	Notes
TR987	X			Finalize startup activities for FDA-approved Ph 3 trial
		X	X	Initiate Ph 3 venous leg ulcer trial (in 2024)
TR Pro+	X	X	X	Ramp up commercialization for this DTC cosmeceutical



Vectus Biosystems Ltd (VBS.AX)



SUMMARY & FOCUS AREAS

Vectus Biosystems Limited was formed with technology from Dr Karen Duggan's lab focused on reversing fibrosis caused by hypertension and other chronic diseases. The company holds patents around the Vasoactive Intestinal Peptide (VIP) and its fragments and intends to remain an R&D-focused company, and license its current and future technologies.

COMPANY CHEAT SHEET

Vectus was founded in 2005 from work in Dr. Karen Duggan's lab and listed on the Australian Securities Exchange (ASX) in 2016.

Therapeutic areas	Cardiology
Lead asset	VB0004 (antihypertensive)
Platform	Yes

Financial summary (AUD)	
Market cap	\$16.0M
Price	\$0.30
52wk hi	\$0.79
52wk lo	\$0.27
Avg vol (3m)	5.1K
Shares	53.2M
Cash	\$1.8M

<http://www.vectusbiosystems.com.au/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
VB0004						Ongoing Ph 1b trial in mild / mod hypertension
						Ongoing preclinical work in additional indications
VB4-A32						Ongoing IND-enabling work in hepatic fibrosis

Catalysts	1Q'24	2Q'24	2H'24	Notes
VB0004	X	X		Anticipated updates for ongoing Ph 1b in hypertension
VB4-A32	X	X	X	Continue progressing IND-enabling work in hepatic fibrosis
VB4-A79	X	X	X	Continue progressing preclinical work in pulmonary fibrosis



Zelira Therapeutics (ZLD.AX)



SUMMARY & FOCUS AREAS

Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company. The company owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets.

COMPANY CHEAT SHEET

Zelira was founded in 2003 by current Chairman Osagie O. Imasogie and listed on the Australian Securities Exchange (ASX) in July 2003.

Therapeutic areas	Neurology
Lead asset	HOPE (cannabinoid)
Platform	Yes

Financial summary (AUD)	
Market cap	\$10.2M
Price	\$0.90
52wk hi	\$3.35
52wk lo	\$0.90
Avg vol (3m)	4.7K
Shares	11.3M
Cash	\$1.0M

<https://zeliratx.com/>

Lead Pipeline	Pre	Ph 1	Ph 2	Ph 3	Mkt	Notes
HOPE						Marketed OTC as a tincture. Planned Ph 2/3 trial in autism
ZLT-L-007						Completed early-stage trial in diabetic nerve pain

Catalysts	1Q'24	2Q'24	2H'24	Notes
HOPE	X			Completion of target product profile with US CRO
		X	X	Begin US Ph 2/3 trial (HOPE 1) in autism spectrum disorder
ZLT-L-007	X	X		FDA conversations on progressing to "formal" FDA trials

